Nanoparticles-mediated reoxygenation strategy relieves tumor hypoxia for enhanced cancer therapy

Wang, Hong; Li, Jie; Wang, Yuqi; Gong, Xianzu; Xu, Xiaoxuan; Wang, Jiaoying; Li, Yaping; Sha, Xianyi; Zhang, Zhiwen

doi:10.1016/j.jconrel.2019.12.028

Cited by 98 publications

(62 citation statements)

References 112 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Likewise, more NP-mediated oxygen carrying and oxygen generation to relieve cancer niche hypoxia were summarized by Wang et al. 42 , including PFC- and Hb-based oxygen-carrying NPs, self-decomposed and photocatalyst-based oxygen-generating NPs.…”

Section: Ddss For Targeting Csc Nichementioning

confidence: 99%

Recent advances in drug delivery systems for targeting cancer stem cells

Duan

Liu

Gao

et al. 2021

Acta Pharmaceutica Sinica B

176

107

View full text Add to dashboard Cite

Cancer stem cells (CSCs) are a subpopulation of cancer cells with functions similar to those of normal stem cells. Although few in number, they are capable of self-renewal, unlimited proliferation, and multi-directional differentiation potential. In addition, CSCs have the ability to escape immune surveillance. Thus, they play an important role in the occurrence and development of tumors, and they are closely related to tumor invasion, metastasis, drug resistance, and recurrence after treatment. Therefore, specific targeting of CSCs may improve the efficiency of cancer therapy. A series of corresponding promising therapeutic strategies based on CSC targeting, such as the targeting of CSC niche, CSC signaling pathways, and CSC mitochondria, are currently under development. Given the rapid progression in this field and nanotechnology, drug delivery systems (DDSs) for CSC targeting are increasingly being developed. In this review, we summarize the advances in CSC-targeted DDSs. Furthermore, we highlight the latest developmental trends through the main line of CSC occurrence and development process; some considerations about the rationale, advantages, and limitations of different DDSs for CSC-targeted therapies were discussed.

show abstract

Section: Ddss For Targeting Csc Nichementioning

confidence: 99%

Recent advances in drug delivery systems for targeting cancer stem cells

Duan

Liu

Gao

et al. 2021

Acta Pharmaceutica Sinica B

176

107

View full text Add to dashboard Cite

show abstract

“…Therefore, in the recent years, nanoparticle‐based reoxygenation strategy has also been proposed to relieve hypoxia and improve therapeutic outcomes of PDT and chemotherapy. [ 34 ] The potential of exploiting tumor hypoxia as a therapeutic target is now well recognized. Many hypoxia‐responsive prodrugs and nanoparticles have been developed for tumor‐targeted therapy.…”

Section: Hypoxic Microenvironment Of Tumor Tissuementioning

confidence: 99%

Tumor Microenvironment Sensitive Nanocarriers for Bioimaging and Therapeutics

Park

Saravanakumar

Kim

et al. 2020

Adv Healthcare Materials

View full text Add to dashboard Cite

The tumor microenvironment (TME), which is composed of cancer cells, stromal cells, immune cells, and extracellular matrices, plays an important role in tumor growth and progression. Thus, targeting the TME using a well‐designed nano‐drug delivery system is emerging as a promising strategy for the treatment of solid tumors. Compared to normal tissues, the TME presents several distinguishable physiological features such as mildly acidic pH, hypoxia, high level of reactive oxygen species, and overexpression of specific enzymes, that are exploited as stimuli to induce specific changes in the nanocarrier structures, and thereby facilitates target‐specific delivery of imaging or chemotherapeutic agents for the early diagnosis or effective treatment, respectively. Recently, smart nanocarriers that respond to more than one stimulus in the TME have also been designed to elicit a more desirable spatiotemporally controlled drug release. This review highlights the recent progress in TME‐sensitive nanocarriers designed for more efficient tumor therapy and imaging. In particular, the design strategies, challenges, and critical considerations involved in the fabrication of TME‐sensitive nanocarriers, along with their in vitro and in vivo evaluations are discussed.

show abstract

“…Nanotechnology has been increasingly used to reverse tumor hypoxic microenvironment ( 42 , 53 , 54 ). Modified nanoparticles could attenuate the unfavorable factors by normalizing oxygen levels through tumor vascular normalization ( 55 , 56 ), external oxygen delivery, capture and delivery of oxygen from the lungs and generation of oxygen through catalysis of water ( 47 ).…”

Section: Applicable Systems Of Nanomodified Immunotherapymentioning

confidence: 99%

“…Oxygen-carrying is a direct strategy in which nanocarriers load oxygen in oxygen-rich areas and release oxygen in hypoxic areas depending on the partial oxygen pressure ( Figure 2 ) ( 53 ). Perfluorocarbon is a safe O 2 carrier that has been already demonstrated in clinic, and the encapsulation of perfluorocarbon with albumin enhanced its accumulation in the tumor site and rapidly released the oxygen that was physically dissolved ( 69 ).…”

Section: Applicable Systems Of Nanomodified Immunotherapymentioning

confidence: 99%

Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy

Peng

et al. 2020

Front. Immunol.

View full text Add to dashboard Cite

Immunotherapies have been accelerating the development of anti-cancer clinical treatment, but its low objective responses and severe off-target immune-related adverse events (irAEs) limit the range of application. Strategies to remove these obstacles primarily focus on the combination of different therapies and the exploitation of new immunotherapeutic agents. Nanomedicine potentiates the effects of activating immune cells selectively and reversing tumor induced immune deficiency microenvironment through multiple mechanisms. In the last decade, a variety of nano-enabled tumor immunotherapies was under clinical investigation. As time goes by, the advantages of nanomedicine are increasingly prominent. With the continuous development of nanotechnology, nanomedicine will offer more distinctive perspectives in imaging diagnosis and treatment of tumors. In this Review, we wish to provide an overview of tumor immunotherapy and the mechanisms of nanomaterials that aim to enhance the efficacy of tumor immunotherapy under development or in clinic treatment.

show abstract

Nanoparticles-mediated reoxygenation strategy relieves tumor hypoxia for enhanced cancer therapy

Cited by 98 publications

References 112 publications

Recent advances in drug delivery systems for targeting cancer stem cells

Recent advances in drug delivery systems for targeting cancer stem cells

Tumor Microenvironment Sensitive Nanocarriers for Bioimaging and Therapeutics

Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy

Contact Info

Product

Resources

About